CIDP has no biomarkers ... and differential diagnostic exclusions are not respected, electrodiagnostic testing is not ...

Chronic inflammatory demyelinating polyneuropathy (CIPD) can have a substantial impact on patients everyday life and, ...

In the CIDP study, patients had an average 1.8-point improvement ... They could ask for approval of batoclimab in thyroid eye disease, where it's currently in Phase 3 testing.

The phase IIb study is evaluating batoclimab in CIDP patients whose disease had worsened during standard-of-care treatment. CIDP is a rare autoimmune neurological disorder that causes progressive ...

He noted the significant early impact on CIDP and progress in clinical milestones, including advancing empasiprubart and efgartigimod into Phase III programs. Van Hauwermeiren announced that 2025 ...

Netherlands biotech Argenx has a second FDA approval for its FcRn inhibitor Vyvgart Hytrulo, adding a new indication in chronic inflammatory demyelinating polyneuropathy (CIDP) for a drug that it ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

One type, the immune-mediated demyelinating neuropathies, includes Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and ...

The lack of detailed data or outcomes from the Phase 3 study of batoclimab in MG and the Phase 2b study in CIDP prior to the webcast may raise concerns among investors about the effectiveness of ...

Today’s results show that deeper IgG reduction leads to deeper responses in MG and CIDP. Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction ...

Chronic inflammatory demyelinating polyneuropathy is an immune-mediated neuropathy that affects the peripheral motor and sensory nerves. The symptoms are of a slowly progressive numbness and tingling ...